Crizotinib, a first-generation anaplastic lymphoma kinase (ALK) inhibitor, and ceritinib and alectinib, the second-generation ALK inhibitors, have been used as the first-line treatment for non-small-cell lung cancer (NSCLC) carrying ALK or ROS1 rearrangements [1]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.